OncoMatch/Clinical Trials/NCT04842162
Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery
Is NCT04842162 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies indocyanine green for head and neck cancer.
Treatment: indocyanine green — Assess the sensitivity of real-time near-infrared fluorescence imaging to detect microscopic residual disease in the operating room after a complete macroscopic surgical resection of head and neck cancers
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Lab requirements
Kidney function
Advanced renal failure (creatinine > 1.5mg/dL) [excluded]
Cardiac function
Documented coronary artery disease [excluded]
Advanced renal failure (creatinine > 1.5mg/dL) [excluded]; Documented coronary artery disease [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify